IL1B and myocardial infarction: In fact, the outcome of the CANTOS trial (14), is partly built on the specific inclusion of post-MI patients with a residual inflammatory risk mirrored by high sensitive C-reactive protein levels, reflecting high IL-1ß levels (105), and their hereto treatment with the IL-1ß antibody canakinumab.